OKYO Pharma LimitedNASDAQ: OKYO

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

· Issued by OKYO Pharma Limited via GlobeNewswire

Summary by 6ix AI

OKYO Pharma Limited, a clinical-stage drug developer working on treatments for neuropathic corneal pain (long-lasting eye pain caused by nerve damage in the cornea) and front-of-eye diseases, will present at Eyecelerator on October 8, 2026 in New Orleans, Louisiana, and take part in two other eye-care conferences.

Key details

  • CEO Robert J. Dempsey is scheduled to present "Addressing Unmet Needs in Corneal and Anterior Segment Diseases" on Thursday, October 8, 2026, at 1:29 PM CT in the Anterior Segment breakout, Room 243-245, moderated by Julie Schallhorn, MD, MS and Kendall Donaldson, MD.
  • The leadership team will attend the American Academy of Optometry meeting, September 30 to October 1 in Anaheim, to meet optometry experts.
  • The leadership team will attend the American Academy of Ophthalmology meeting, October 9-12 in New Orleans, to meet ophthalmology experts.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/okyo-pharma-presents-and-participates-at-upcoming-ophthalmic-scientific-conferences

  • OKYO demonstrates continued commitment to optometry and ophthalmology

LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.

Upcoming Scientific Conferences:

Eyecelerator: October 8, 2026New Orleans, Louisiana

Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment DiseasesPresentation Date/Time: Thursday, October 8, 2026, 1:29 PM CTBreakout: Anterior Segment, Room 243-245Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO PharmaModerators: Julie Schallhorn, MD, MS; Kendall Donaldson, MD

American Academy of Optometry takes place September 30 - October 1 in Anaheim where the leadership team will engage leading optometric experts.

American Academy of Ophthalmology takes place October 9-12 in New Orleans where the leadership team will engage with leading ophthalmology experts.

The Company's continued presence at leading ophthalmic meetings supports its commitment to engaging both optometrists and ophthalmologists, who both play a role in the diagnosis and care of patients with neuropathic corneal pain (NCP).

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma LtdPaul SpencerBusiness Development and Investor Relations+44 (0) 207 495 2379Email: [email protected]

OKYO Pharma Limited on 6ix

Earlier from OKYO Pharma

Later from OKYO Pharma

All OKYO Pharma news releases